Assessment of Real World Avelumab Uptake for Patients with Urothelial Carcinoma
At the 2023 ASCO Annual Meeting, Helen Moon, MD, Kaiser Permanente, Riverside, California, discusses results from a study investigating the real world response rates of patients with urothelial carcinoma treated with first-line platinum-based chemotherapy, to assess the uptake of avelumab maintenance therapy.
Based on the JAVELIN-Bladder-100 trial, standard of care for patients with urothelial carcinoma has been established as first-line platinum-based chemotherapy followed by avelumab first-line maintenance. However, with this real world dataset, Dr Moon and colleagues found that only approximately 20% of patients with urothelial carcinoma who responded on platinum-based chemotherapy proceeded to avelumab maintenance.
Source:
Moon HH, Aragon-Ching JB, Thompson A, et al. Real-world response rates and clinical outcomes of patients treated with first-line (1L) platinum-based chemotherapy (PBC) in advanced urothelial cancer (aUC). Presented at 2023 ASCO Annual Meeting; June 2-6, 2023; Chicago, Illinois.
